Citius Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $11.20M
- P/E (TTM)
- –
- Dividend yield
- –
About Citius Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of critical care therapeutic products. Its operations center on oncology, anti-infectives used in adjunct cancer care, and specialized prescription therapies. The company's portfolio features an approved oncology treatment, denileukin diftitox (marketed as LYMPHIR), for patients with persistent or recurrent cutaneous T-cell lymphoma. Additionally, its late-stage development pipeline includes Mino-Lok, an antibiotic lock solution engineered to salvage infected central venous catheters, Halo-Lido, a topical anti-inflammatory and anesthetic formulation for hemorrhoids, and a mesenchymal stem cell therapy for acute respiratory distress syndrome.
The company delivers its commercial therapies to adult patients diagnosed with persistent or recurrent cutaneous T-cell lymphoma. Its investigational treatments target hospitalized or outpatient individuals requiring catheter salvage or therapeutic relief for acute respiratory distress syndrome and hemorrhoids. Corporate headquarters and principal executive offices are located in Cranford, New Jersey.
Summary of the business section of Citius Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Citius Pharmaceuticals, Inc.
- Founded
- 2007
- Headquarters
- Cranford, NJ
- Address
- 11 Commerce Drive, 1st Floor 07016
- Phone
- (908) 967-6676
- Website
- citiuspharma.com
- Employees
- 23, Sep 30, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- September 30
- Auditor
- Wolf& Company, P.C., Boston, Massachusetts
Stock & identifiers
- Ticker
- CTXR
- Exchange
- Nasdaq
- IPO date
- Oct 2, 2014
- Shares outstanding
- 27M, Aug 13, 2026
- Public float
- $11.39M, Mar 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Dec 27, 2024; 1-for-25 reverse, Nov 26, 2024; 1-for-15 reverse, Aug 14, 2017; 1-for-15 reverse, Jun 9, 2017
- SEC CIK
- 1506251
- CUSIP
- 17322U306
- ISIN
- US17322U3068
- LEI
- 5493005C10W36P4KQP40
- EIN
- 27-3425913
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Leonard L. Mazur | Chief Executive Officer, Director | 410,214 |
| Myron Z. Holubiak | Vice Chairman, Director | 79,690 |
| Jaime Bartushak | Chief Financial Officer | 60,353 |
| Myron Czuczman | Chief Medical Officer | – |
| Dennis M. McGrath | Director | – |
| Robert Joseph Smith | Director | – |
| Suren G. Dutia | Director | – |
| Eugene Myron Holuka | Director | 2,367 |
| Carol Webb | Director | 11,835 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Leonard Mazur | $4.51M | $7.12M | $2.48M | $4 | – |
| FY2024 Leonard Mazur | $3.52M | -$2.04M | $1.97M | $41 | – |
| FY2023 Leonard Mazur | $1.98M | $6.29M | $1.38M | $57 | – |
| FY2022 Leonard Mazur | $1.19M | $479.35K | $848.42K | $60 | – |
| FY2022 Myron Holubiak | $1.24M | $529.35K | $848.42K | $60 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of September 30, 2025, we had 23 employees”
Corporate history
Events identified from SEC filings